Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H13NO5.BrH |
| Molecular Weight | 260.083 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Br.N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO
InChI
InChIKey=ASABJCIAWRGCPT-BTVCFUMJSA-N
InChI=1S/C6H13NO5.BrH/c7-3(1-8)5(11)6(12)4(10)2-9;/h1,3-6,9-12H,2,7H2;1H/t3-,4+,5+,6+;/m0./s1
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C6H13NO5 |
| Molecular Weight | 179.1711 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/npp/glucosamine.html
Sources: https://www.drugs.com/npp/glucosamine.html
Glucosamine is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. Glucosamine is part of the structure of the polysaccharides chitosan and chitin, which compose the exoskeletons of crustaceans and other arthropods, as well as the cell walls of fungi and many higher organisms. Glucosamine is one of the most abundant monosaccharides. It is produced commercially by the hydrolysis of crustacean exoskeletons or, less commonly, by fermentation of a grain such as corn or wheat. Oral glucosamine is a dietary supplement and is not a pharmaceutical drug. It is illegal in the US to market any dietary supplement as a treatment for any disease or condition. Glucosamine is marketed to support the structure and function of joints, and the marketing is targeted to people suffering from osteoarthritis. Commonly sold forms of glucosamine are glucosamine sulfate, glucosamine hydrochloride, and N-acetylglucosamine. Of the three commonly available forms of glucosamine, only glucosamine sulfate is given a "likely effective" rating for treating osteoarthritis. Glucosamine is often sold in combination with other supplements such as chondroitin sulfate and methylsulfonylmethane. Glucosamine, along with commonly used chondroitin, is not routinely prescribed to treat people who have symptomatic osteoarthritis of the knee, as there is insufficient evidence that this treatment is helpful. One clinical study over three years showed that glucosamine in doses of 1500 mg per day is safe to use. Glucosamine with or without chondroitin elevates the international normalized ratio (INR) in individuals who are taking the blood thinner, warfarin. It may also interfere with the efficacy of chemotherapy for treating cancer symptoms. Adverse effects may include stomach upset, constipation, diarrhea, headache, and rash. There are case reports of people who have chronic liver disease and a worsening of their condition with glucosamine supplementation. Glucosamine is naturally present in the shells of shellfish, animal bones, bone marrow, and fungi. D-Glucosamine is made naturally in the form of glucosamine-6-phosphate, and is the biochemical precursor of all nitrogen-containing sugars. Specifically in humans, glucosamine-6-phosphate is synthesized from fructose 6-phosphate and glutamine by glutamine—fructose-6-phosphate transaminase as the first step of the hexosamine biosynthesis pathway. The end-product of this pathway is uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), which is then used for making glycosaminoglycans, proteoglycans, and glycolipids. As the formation of glucosamine-6-phosphate is the first step for the synthesis of these products, glucosamine may be important in regulating their production; however, the way that the hexosamine biosynthesis pathway is actually regulated, and whether this could be involved in contributing to human disease remains unclear.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1697668 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23571415 |
|||
Target ID: CHEMBL1743121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23571415 |
|||
Target ID: CHEMBL5685 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18788725 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Glucosamine Approved UseUnknown |
|||
| Primary | Glucosamine Approved UseUnknown |
|||
| Primary | Oral Lichen Planus Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2224 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32901283/ |
1500 mg 1 times / day steady-state, oral dose: 1500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
GLUCOSAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2125 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32901283/ |
1500 mg 1 times / day steady-state, oral dose: 1500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
GLUCOSAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1069.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16168682/ |
750 mg 1 times / day steady-state, oral dose: 750 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
GLUCOSAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1601.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16168682/ |
1500 mg 1 times / day steady-state, oral dose: 1500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
GLUCOSAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2503.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16168682/ |
3000 mg 1 times / day steady-state, oral dose: 3000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
GLUCOSAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
16874 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32901283/ |
1500 mg 1 times / day steady-state, oral dose: 1500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
GLUCOSAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
16718 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32901283/ |
1500 mg 1 times / day steady-state, oral dose: 1500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
GLUCOSAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
9697 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16168682/ |
750 mg 1 times / day steady-state, oral dose: 750 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
GLUCOSAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
14564 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16168682/ |
1500 mg 1 times / day steady-state, oral dose: 1500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
GLUCOSAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
22095 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16168682/ |
3000 mg 1 times / day steady-state, oral dose: 3000 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
GLUCOSAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32901283/ |
1500 mg 1 times / day steady-state, oral dose: 1500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
GLUCOSAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32901283/ |
1500 mg 1 times / day steady-state, oral dose: 1500 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
GLUCOSAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
100% |
unknown |
GLUCOSAMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
100% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22112180/ |
GLUCOSAMINE plasma | Homo sapiens |
Doses
| Dose | Population | Adverse events |
|---|---|---|
3000 mg 1 times / day steady-state, oral Highest studied dose Dose: 3000 mg, 1 times / day Route: oral Route: steady-state Dose: 3000 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
|
1500 mg 1 times / day multiple, oral Recommended Dose: 1500 mg, 1 times / day Route: oral Route: multiple Dose: 1500 mg, 1 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. | 2008-09 |
|
| Disease-modifying effects of glucosamine HCl involving regulation of metalloproteinases and chemokines activated by interleukin-1beta in human primary synovial fibroblasts. | 2008-05-01 |
|
| Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factor-kappaB signaling. | 2008-03 |
|
| A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial. | 2008-02-17 |
|
| Sulfated glucosamine inhibits oxidation of biomolecules in cells via a mechanism involving intracellular free radical scavenging. | 2008-01-28 |
|
| Glucosamine and its N-acetyl-phenylalanine derivative prevent TNF-alpha-induced transcriptional activation in human chondrocytes. | 2008-01-05 |
|
| Influence of glucosamine sulphate on oxidative stress in human osteoarthritic chondrocytes: effects on HO-1, p22(Phox) and iNOS expression. | 2008-01 |
|
| [Determination of glucosamine hydrochloride in complex formula by RP-HPLC coupled with evaporative light scattering detection]. | 2007-11 |
|
| The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes. | 2007-11 |
|
| Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. | 2007-11 |
|
| Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. | 2007-10-31 |
|
| Evaluation of the suppressive actions of glucosamine on the interleukin-1beta-mediated activation of synoviocytes. | 2007-10 |
|
| Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner. | 2007-09-21 |
|
| Treatment of primary and secondary osteoarthritis of the knee. | 2007-09 |
|
| [A comparison study on the physical/chemical properties and immunomodulatory activities of mycelial polysaccharide extracts from five Ganoderma species]. | 2007-08 |
|
| Modulation of articular chondrocyte proliferation and anionic glycoconjugate synthesis by glucosamine (GlcN), N-acetyl GlcN (GlcNAc) GlcN sulfate salt (GlcN.S) and covalent glucosamine sulfates (GlcN-SO4). | 2007-08 |
|
| [Effect of glucosamine sulfate on the analgesic and ulcerogenic activity of ketoprofen]. | 2007-07-27 |
|
| [Efficacy and safety evaluation of glucosamine hydrochloride in the treatment of osteoarthritis]. | 2007-07-15 |
|
| Sulfated glucosamine inhibits MMP-2 and MMP-9 expressions in human fibrosarcoma cells. | 2007-07-15 |
|
| Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. | 2007-07 |
|
| Glucosamine for pain in osteoarthritis: why do trial results differ? | 2007-07 |
|
| Collagen Synthesis in tenocytes, ligament cells and chondrocytes exposed to a combination of Glucosamine HCl and chondroitin sulfate. | 2007-06 |
|
| Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. | 2007-06 |
|
| The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis. | 2007-05 |
|
| Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-kappaB. | 2007-05 |
|
| Establishment of a novel corneal endothelial cell line from domestic rabbit, Oryctolagus curiculus. | 2007-04 |
|
| Preparation of glucosamine from exoskeleton of shrimp and predicting production yield by response surface methodology. | 2007-03-21 |
|
| Factors affecting trypanosome maturation in tsetse flies. | 2007-02-21 |
|
| Systematic review of clinical trials of treatments for osteoarthritis in dogs. | 2007-02-15 |
|
| [The influence of experimental therapy on the dynamics of endogenous glucosamine content in laboratory animals with nephropathy]. | 2007-01-11 |
|
| Effects of glucosamine administration on patients with rheumatoid arthritis. | 2007-01 |
|
| Glucosamine hydrochloride for the treatment of osteoarthritis symptoms. | 2007 |
|
| Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. | 2007 |
|
| Glucosamine affects intracellular signalling through inhibition of mitogen-activated protein kinase phosphorylation in human chondrocytes. | 2007 |
|
| Glucosamine prevents in vitro collagen degradation in chondrocytes by inhibiting advanced lipoxidation reactions and protein oxidation. | 2007 |
|
| Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. | 2007 |
|
| An analysis of high glucose and glucosamine-induced gene expression and oxidative stress in renal mesangial cells. | 2006-12-21 |
|
| Glucosamine sulfate inhibits proinflammatory cytokine-induced icam-1 production in human conjunctival cells in vitro. | 2006-12 |
|
| Enhanced chondrogenic differentiation of murine embryonic stem cells in hydrogels with glucosamine. | 2006-12 |
|
| Glucosamine sulfate inhibits leukocyte adhesion in response to cytokine stimulation of retinal pigment epithelial cells in vitro. | 2006-11 |
|
| Evidence-based practice: review of clinical evidence on the efficacy of glucosamine and chondroitin in the treatment of osteoarthritis. | 2006-10 |
|
| Glucosamine sulfate-induced apoptosis in chronic myelogenous leukemia K562 cells is associated with translocation of cathepsin D and downregulation of Bcl-xL. | 2006-10 |
|
| Double blind investigation of the effects of oral supplementation of combined glucosamine hydrochloride (GHCL) and chondroitin sulphate (CS) on stride characteristics of veteran horses. | 2006-08 |
|
| Arthritic disease suppression and cartilage protection with glycosaminoglycan polypeptide complexes (Peptacans) derived from the cartilage extracellular matrix: a novel approach to therapy. | 2006-08 |
|
| An optimized reverse-phase high performance liquid chromatographic method for evaluating percutaneous absorption of glucosamine hydrochloride. | 2006-05-03 |
|
| Determination of the degree of acetylation of chitosan by UV spectrophotometry using dual standards. | 2006-05-01 |
|
| Glucosamine sulfate inhibits TNF-alpha and IFN-gamma-induced production of ICAM-1 in human retinal pigment epithelial cells in vitro. | 2006-02 |
|
| Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. | 2006 |
|
| Inhibitory effects of glucosamine on lipopolysaccharide-induced activation in microglial cells. | 2005-12 |
|
| [Experience with glucosamine hydrochloride in the treatment of patients with osteoarthrosis]. | 2005 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/npp/glucosamine.html
In clinical studies of arthritis, glucosamine dosage has typically been 1.5 g/day, as a single dose or in divided doses.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10891367
To induce insulin resistance 3T3-L1 adipocytes were treated with DMEM containing 10% FBS and 2 mM glucosamine, and in the absence of glucose, glutamine, and insulin. Since glucosamine bypasses the GFAT step to enter the hexosamine pathway, glutamine is not needed for glucosamineinduced insulin resistance
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 11:19:36 GMT 2025
by
admin
on
Wed Apr 02 11:19:36 GMT 2025
|
| Record UNII |
47BY4DVA8E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
47BY4DVA8E
Created by
admin on Wed Apr 02 11:19:36 GMT 2025 , Edited by admin on Wed Apr 02 11:19:36 GMT 2025
|
PRIMARY | |||
|
910542-39-1
Created by
admin on Wed Apr 02 11:19:36 GMT 2025 , Edited by admin on Wed Apr 02 11:19:36 GMT 2025
|
PRIMARY | |||
|
300000025700
Created by
admin on Wed Apr 02 11:19:36 GMT 2025 , Edited by admin on Wed Apr 02 11:19:36 GMT 2025
|
PRIMARY | |||
|
87979753
Created by
admin on Wed Apr 02 11:19:36 GMT 2025 , Edited by admin on Wed Apr 02 11:19:36 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|